Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1996 Dec;89(4):619–626. doi: 10.1046/j.1365-2567.1996.d01-773.x

Role of prolactin in the in vitro development of interleukin-2-driven anti-tumoural lymphokine-activated killer cells.

L Matera 1, G Bellone 1, J J Lebren 1, P A Kelly 1, E L Hooghe Peters 1, P F Di Celle 1, R Foa 1, M Contarini 1, G Avanzi 1, V Asnaghi 1
PMCID: PMC1456571  PMID: 9014831

Abstract

Exogenous prolactin (PRL) has been shown to synergize with low-dose interleukin-2 (IL-2) and induce the proliferation and lymphokine-activated killer (LAK) maturation of natural killer (NK) cells. PRL itself can also generate LAK activity. Here we show that its local production occurs during, and is necessary for, LAK development. IL-2-stimulated peripheral blood mononuclear cells (PBMC) and purified NK cells were exposed to anti-human (h)PRL antiserum, and residual LAK activity was measured on day 7 against the promyelocytic leukaemia cell line HL-60. Inhibition of LAK activity was much more evident in PBMC compared with NK cell cultures (47% decrease. P - 0.013 and 18.5% decrease. P = 0.048, respectively). Up-modulation of a 32S-methionine-labelled 27,000 MW protein was detected in the lysates and supernatants of IL-2-stimulated PBMC immunoprecipitated with an anti-PRL antiserum. By contrast, the cytoplasmic PRL immunoreactivity observed in freshly isolated NK cells and in IL-2-stimulated, but not unstimulated, NK cell cultures was not associated with PRL gene activation, and can thus be referred to internalized PRL. Preferential re-uptake of externally derived PRL by IL-2-stimulated NK cells was also indicated by up-modulation of the PRL receptor. These data, as a whole, indicate that the PRL promotion of LAK differentiation is mainly mediated by paracrine secretion, with a minor contribution from internalized PRL.

Full text

PDF
619

Images in this article

621Figure 3
on p.621
622Figure 4
on p.622
623Figure 5
on p.623
624Figure 6
on p.624
625Figure 7
on p.625

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cesano A., Oberholtzer E., Contarini M., Geuna M., Bellone G., Matera L. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors. Immunopharmacology. 1994 Jul-Aug;28(1):67–75. doi: 10.1016/0162-3109(94)90040-x. [DOI] [PubMed] [Google Scholar]
  2. Clevenger C. V., Russell D. H., Appasamy P. M., Prystowsky M. B. Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci U S A. 1990 Aug;87(16):6460–6464. doi: 10.1073/pnas.87.16.6460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cole E. S., Nichols E. H., Lauziere K., Edmunds T., McPherson J. M. Characterization of the microheterogeneity of recombinant primate prolactin: implications for posttranslational modifications of the hormone in vivo. Endocrinology. 1991 Nov;129(5):2639–2646. doi: 10.1210/endo-129-5-2639. [DOI] [PubMed] [Google Scholar]
  4. Croze F., Walker A., Friesen H. G. Stimulation of growth of Nb2 lymphoma cells by interleukin-2 in serum-free and serum-containing media. Mol Cell Endocrinol. 1988 Feb;55(2-3):253–259. doi: 10.1016/0303-7207(88)90140-2. [DOI] [PubMed] [Google Scholar]
  5. Dardenne M., de Moraes M. do C., Kelly P. A., Gagnerault M. C. Prolactin receptor expression in human hematopoietic tissues analyzed by flow cytofluorometry. Endocrinology. 1994 May;134(5):2108–2114. doi: 10.1210/endo.134.5.8156910. [DOI] [PubMed] [Google Scholar]
  6. Delhase M., Vergani P., Malur A., Velkeniers B., Teugels E., Trouillas J., Hooghe-Peters E. L. Pit-1/GHF-1 expression in pituitary adenomas: further analogy between human adenomas and rat SMtTW tumours. J Mol Endocrinol. 1993 Oct;11(2):129–139. doi: 10.1677/jme.0.0110129. [DOI] [PubMed] [Google Scholar]
  7. Gala R. R. Prolactin and growth hormone in the regulation of the immune system. Proc Soc Exp Biol Med. 1991 Oct;198(1):513–527. doi: 10.3181/00379727-198-43286b. [DOI] [PubMed] [Google Scholar]
  8. Galandrini R., Palmieri G., Piccoli M., Frati L., Santoni A. CD16-mediated p21ras activation is associated with Shc and p36 tyrosine phosphorylation and their binding with Grb2 in human natural killer cells. J Exp Med. 1996 Jan 1;183(1):179–186. doi: 10.1084/jem.183.1.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gilmour K. C., Reich N. C. Receptor to nucleus signaling by prolactin and interleukin 2 via activation of latent DNA-binding factors. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6850–6854. doi: 10.1073/pnas.91.15.6850. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Giss B. J., Walker A. M. Mammotroph autoregulation: intracellular fate of internalized prolactin. Mol Cell Endocrinol. 1985 Oct;42(3):259–267. doi: 10.1016/0303-7207(85)90057-7. [DOI] [PubMed] [Google Scholar]
  11. Grimm E. A., Owen-Schaub L. The IL-2 mediated amplification of cellular cytotoxicity. J Cell Biochem. 1991 Apr;45(4):335–339. doi: 10.1002/jcb.240450405. [DOI] [PubMed] [Google Scholar]
  12. Haendler B., Hofer-Warbinek R., Hofer E. Complementary DNA for human T-cell cyclophilin. EMBO J. 1987 Apr;6(4):947–950. doi: 10.1002/j.1460-2075.1987.tb04843.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hartmann D. P., Holaday J. W., Bernton E. W. Inhibition of lymphocyte proliferation by antibodies to prolactin. FASEB J. 1989 Aug;3(10):2194–2202. doi: 10.1096/fasebj.3.10.2787766. [DOI] [PubMed] [Google Scholar]
  14. Hooghe R., Delhase M., Vergani P., Malur A., Hooghe-Peters E. L. Growth hormone and prolactin are paracrine growth and differentiation factors in the haemopoietic system. Immunol Today. 1993 May;14(5):212–214. doi: 10.1016/0167-5699(93)90165-h. [DOI] [PubMed] [Google Scholar]
  15. Kelly P. A., Djiane J., Postel-Vinay M. C., Edery M. The prolactin/growth hormone receptor family. Endocr Rev. 1991 Aug;12(3):235–251. doi: 10.1210/edrv-12-3-235. [DOI] [PubMed] [Google Scholar]
  16. Kim S., Haas G. P., Hillman G. G. Development of immunotherapy for the treatment of malignancies refractory to conventional therapies. Cytokines Mol Ther. 1996 Mar;2(1):13–19. [PubMed] [Google Scholar]
  17. Matera L., Bellone G., Contarini M. Synthesis of a prolactin-like peptide by natural killer cells: positive regulation by CD16 and exogenous prolactin. Cell Mol Biol (Noisy-le-grand) 1992 Dec;38(8):915–920. [PubMed] [Google Scholar]
  18. Matera L., Cesano A., Bellone G., Oberholtzer E. Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes. Brain Behav Immun. 1992 Dec;6(4):409–417. doi: 10.1016/0889-1591(92)90039-q. [DOI] [PubMed] [Google Scholar]
  19. Matera L., Cesano A., Muccioli G., Veglia F. Modulatory effect of prolactin on the DNA synthesis rate and NK activity of large granular lymphocytes. Int J Neurosci. 1990 Apr;51(3-4):265–267. doi: 10.3109/00207459008999716. [DOI] [PubMed] [Google Scholar]
  20. Matera L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci. 1996;59(8):599–614. doi: 10.1016/0024-3205(96)00225-1. [DOI] [PubMed] [Google Scholar]
  21. Matera L., Muccioli G., Cesano A., Bellussi G., Genazzani E. Prolactin receptors on large granular lymphocytes: dual regulation by cyclosporin A. Brain Behav Immun. 1988 Mar;2(1):1–10. doi: 10.1016/0889-1591(88)90001-3. [DOI] [PubMed] [Google Scholar]
  22. Matera L., Santoli D., Garbarino G., Pegoraro L., Bellone G., Pagliardi G. Modulation of in vitro myelopoiesis by LGL: different effects on early and late progenitor cells. J Immunol. 1986 Feb 15;136(4):1260–1265. [PubMed] [Google Scholar]
  23. Migliorati G., Cannarile L., Herberman R. B., Riccardi C. Effect of various cytokines and growth factors on the interleukin-2-dependent in vitro differentiation of natural killer cells from bone marrow. Nat Immun Cell Growth Regul. 1989;8(1):48–55. [PubMed] [Google Scholar]
  24. Montgomery D. W., Shen G. K., Ulrich E. D., Steiner L. L., Parrish P. R., Zukoski C. F. Human thymocytes express a prolactin-like messenger ribonucleic acid and synthesize bioactive prolactin-like proteins. Endocrinology. 1992 Dec;131(6):3019–3026. doi: 10.1210/endo.131.6.1446637. [DOI] [PubMed] [Google Scholar]
  25. Mukherjee P., Mastro A. M., Hymer W. C. Prolactin induction of interleukin-2 receptors on rat splenic lymphocytes. Endocrinology. 1990 Jan;126(1):88–94. doi: 10.1210/endo-126-1-88. [DOI] [PubMed] [Google Scholar]
  26. Nagler A., Lanier L. L., Phillips J. H. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med. 1990 May 1;171(5):1527–1533. doi: 10.1084/jem.171.5.1527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Okamura H., Zachwieja J., Raguet S., Kelly P. A. Characterization and applications of monoclonal antibodies to the prolactin receptor. Endocrinology. 1989 May;124(5):2499–2508. doi: 10.1210/endo-124-5-2499. [DOI] [PubMed] [Google Scholar]
  28. Pellegrini I., Lebrun J. J., Ali S., Kelly P. A. Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol. 1992 Jul;6(7):1023–1031. doi: 10.1210/mend.6.7.1508218. [DOI] [PubMed] [Google Scholar]
  29. Perussia B. Lymphokine-activated killer cells, natural killer cells and cytokines. Curr Opin Immunol. 1991 Feb;3(1):49–55. doi: 10.1016/0952-7915(91)90076-d. [DOI] [PubMed] [Google Scholar]
  30. Prystowsky M. B., Clevenger C. V. Prolactin as a second messenger for interleukin 2. Immunomethods. 1994 Aug;5(1):49–55. doi: 10.1006/immu.1994.1037. [DOI] [PubMed] [Google Scholar]
  31. Rosenberg S. A. Immunotherapy and gene therapy of cancer. Cancer Res. 1991 Sep 15;51(18 Suppl):5074s–5079s. [PubMed] [Google Scholar]
  32. Russell D. H., Kibler R., Matrisian L., Larson D. F., Poulos B., Magun B. E. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. J Immunol. 1985 May;134(5):3027–3031. [PubMed] [Google Scholar]
  33. Sabharwal P., Glaser R., Lafuse W., Varma S., Liu Q., Arkins S., Kooijman R., Kutz L., Kelley K. W., Malarkey W. B. Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7713–7716. doi: 10.1073/pnas.89.16.7713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sissom J. F., Eigenbrodt M. L., Porter J. C. Anti-growth action on mouse mammary and prostate glands of a monoclonal antibody to prolactin receptor. Am J Pathol. 1988 Dec;133(3):589–595. [PMC free article] [PubMed] [Google Scholar]
  35. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187–376. doi: 10.1016/S0065-2776(08)60664-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Vanhaesebroeck B., Grooten J., Fiers W. An ongoing in vivo immune response affects the abundancy and differentiation of lymphokine-activated killer cell precursors, but does not influence their broad spectrum target reactivity. J Immunol. 1989 Aug 15;143(4):1396–1402. [PubMed] [Google Scholar]
  37. Viselli S. M., Stanek E. M., Mukherjee P., Hymer W. C., Mastro A. M. Prolactin-induced mitogenesis of lymphocytes from ovariectomized rats. Endocrinology. 1991 Aug;129(2):983–990. doi: 10.1210/endo-129-2-983. [DOI] [PubMed] [Google Scholar]
  38. Vujanovic N. L., Yasumura S., Hirabayashi H., Lin W. C., Watkins S., Herberman R. B., Whiteside T. L. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J Immunol. 1995 Jan 1;154(1):281–289. [PubMed] [Google Scholar]
  39. Walker A. M., Montgomery D. W., Saraiya S., Ho T. W., Garewal H. S., Wilson J., Lorand L. Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes. Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3278–3282. doi: 10.1073/pnas.92.8.3278. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES